, exhibit potent activities (MIC ∼0.8 µg/mL, ∼720 times more potent than that of Van itself) against vancomycinresistant enterococci (VRE). The result suggests that combining metal complexation and receptor/ligand interaction offers a useful method to construct multivalent inhibitors.
Introduction
Drug resistance 1 of bacteria poses a serious public health threat and demands effective counter measures. Among promising approaches, 2-8 multi/polyvalencys multiple simultaneous binding of two or more ligands and receptorssis beginning to be explored systematically. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] In the research of multivalency, the ligandreceptor pair of vancomycin (Van)-D-Ala-D-Ala has attracted a great deal of research attention because it relates to vancomycin [19] [20] [21] [22] -resistant enterococci (VRE). 23 , 24 Walsh and colleagues 21, [24] [25] [26] [27] have deciphered the mechanism of vancomycin resistance: VRE mutates its terminal peptides from D-Ala-D-Ala to D-Ala-D-Lac (i.e., D-alanine-D-lactate), which has substantially lowered (∼10 3 times decrease) its affinity to Van. 25, 26, 28 Though Van self-associates to form homodimers upon binding to D-Ala-D-Ala, as elucidated by Williams et al., [29] [30] [31] [32] [33] this noncovalent dimerization of Van alone is insufficient to act against VRE. Griffin et al., 17, 34 Nicolaou et al., 15, 16, 19, 20 and an Eli Lilly group 35 have used organic linkers to synthesize dimers of Van, and demonstrated that covalently linked dimeric Vans exhibit enhanced to potent activity against VRE. It was, however, suggested that the flexibility of the organic linker limited the avidity of the multivalent binding due to the loss of conformational entropy upon binding. 9, 36, 37 We believe that the combination of receptor/ligand interaction and a metal complex, which has special geometry, structural rigidity, and stability, can serve as an alternative approach to minimize the loss of conformational entropy.
To test this strategy, we used a derivative of cisplatin, 38 [Pt(en)(H 2 O) 2 ] 2+ (en: ethylenediamine)sa rigid, square planar metal complexsto form dimeric Vans, and evaluated their activities against VRE. These rigidly linked dimeric Vans exhibit enhanced activities against VRE and are up to ∼720 times more potent against VRE than Van itself in the best case (MIC: 0.8 µg/mL). Our results suggest that combining metal coordination and receptor/ligand interactions [39] [40] [41] [42] offers a useful method to construct multivalent receptors.
Results and Discussions
We chose [Pt(en)] 2+ as the rigid linker to form dimeric Van via complexation due to its extensive developed chemistry, well understood properties, and well preserved planar rigidity. Moreover, the ionic nature of the [Pt(en)] 2+ retainssif not increasessthe solubility of Van in aqueous media, which is necessary for in vitro study. As shown in Scheme 1, commercially available vancomycin (1) reacted with 3-picolylamine, 4-picolylamine, 3-(2-aminoethyl)pyridine, or 1-(3-aminopropyl)imidazole to give the vancomycin carboxamide derivatives (Van-CONH-L) 2a-d in good yields (>65%), respectively. Compounds 2a-d were purified using reversed-phase HPLC according to modified literature procedure 13 and characterized by high field 1 H NMR spectroscopy and mass spectrometry (MS). The attachment of the ligands to the C-terminal of Van 4 ] 10+ , the activity of the mixture of 2d and Zn-(OAc) 2 (4:1, at pH ) 7) against VRE is the same as that of 2d, suggesting that there is no multivalent Van formed by metal complexation when 2d and Zn(OAc) 2 react at the condition of the in vitro experiment. We also did not observe the formation of [Zn(2d) n ] (2n+2)+ (n ) 1-4) by ESI-MS, which is consistent with the observed activity. Figure 1 illustrates the plausible divalent interaction between 4a and the terminal peptides of peptidoglycan precursors. According to this binding mode, both the configuration and rigidity of the dimeric Vans determine their activities. 34 To further understand the structuralactivity relationship, we performed semiquantitative entropy analysis according to the reported methods. 36 Let the conformational entropies (∆S conf ) of Van plus the CONHCH 2 segment to be the same as in 4-7, we compared the ∆S conf of the different linkers (green portions) upon dimerization (assuming the ∆S conf of the metal complex linker to be zero due to the rigidity of [Pt(en)] 2+ ). For example, the ∆S conf of 6 would be the sum of torsional entropies of two C-C bonds and an S-S bond (-ΣS tor ) 7.3 × 2 + 3.5 ) 18.1 J/mol‚K). 36 If we consider only the contribution of ∆S conf to the ∆G and assume that the binding occurs at room temperature, the ratios of binding constants K 4a /K n of 4a-d, 6, and 7 can be calculated. In the case of VanA strains (Table 2) , the ratios of binding constants K 4a /K n agree qualitatively with the MIC values (except 4b). For example, 4a is ∼5 times more potent than 6, 17 which agrees with their ∆S conf values. 4c resembles 4a structurally except that it has an extra CH 2 increasing the flexibility its linker; therefore, 4c exhibits lower activity against VRE. Similarly, additional flexibility in 4d or 7 results in the loss of ∆S conf upon divalent binding and the decrease of its activity. Similar qualitative agreement also exhibits between ∆S conf and the MIC values in the case of VanB strains. The discrepancy between K 4a /K 4b and the MIC of 4b apparently originates from the configuration of 4b, which contributes to the changes of enthalpy. Though other mechanisms cannot be ruled out at this moment, the above analysis supports the hypothesis of the roles of rigidity in divalency for the case of VanA and VanB strains. ∆S conf correlates, however, to little enhancement of the activity of dimeric Vans against vancomycin-sensitive strains and the less resistant VRE (VanC), which has been observed in other systems of divalent Vans, 16, 17, 34 suggesting the enhancement of the activity of dimeric Vans may depend on the composition of peptidoglycan precursors produced by the strains. 43 
Conclusion
In summary, we have demonstrated that a metal complex can be used as a new platform to construct multivalent inhibitors, which are as effective as other rigid linkers [44] [45] [46] used for multivalency. One of the concerns on platinum-based complexes is its cytotoxicity. Our preliminary study has shown that these cis-platinbased divalent Vans are not toxic toward mammalian cells (the detailed work will be published elsewhere). Our future work will examine other metal complex linkers, which may help further elucidate the structural basis of vancomycin resistance, 43, 47 as well as the mechanism of multivalent Vans binding to vancomycinsensitive strains, 48, 49 which has yet to be established.
Experimental Section
General. Chemical reagents and solvents were used as received from commercial sources. Dimethyl sulfoxide (DMSO) was dried over 4 Å molecular sieves and dimethylformamide (DMF) was dried over silica gel. 1 H NMR spectra were obtained at 500 MHz Varian XL-500 in Me2SO-d6 and D2O. Reversedphase HPLC was carried out with Waters 600 Controller and 996 photodiode Array Detector, using XTerra RP18 C18 7 µm columns for both analytical and preparative purpose. HPLC elution employed linear gradients of [0.1% trifluoroacetic acid The mixture was stirred for 20 h at room temperature in dark. During the whole procedure, RP-HPLC was used to monitor the reaction. In the first 3 h, a vancomycin-3-ethylene pyridinecarboxamide peak exists at the elution time of 24 min. With increased time, a new peak at 18 min was found and the peak intensity of the starting material at 24 min was decreased. After 14 h, RP-HPLC indicated that almost all vancomycin-3-ethylene pyridine-carboxamide was consumed completely. Then by quenching the reaction with 10 mL of acetone, a white solid was precipitated. This crude product was filtered and washed three times with acetone and dried under vacuum before it was redissolved in H2O and separated by RP-HPLC. After purification by HPLC, 15.6 mg of pure product was obtained (yield: 75. Synthesis of dimeric Van 6: Following to the same procedure as for 2a, 6.8 mg of cystamide dihydrochloride (30 µmol, 1.0 equiv) was added to a solution of vancomycin hydrochloride (100 mg, 67 µmol, 2.2 equiv) in 1 mL of dry DMSO. The mixture was cooled to 0°C and HBTU (90 µmol, 3 equiv) in 1 mL of DMF was added, followed by DIEA (0.057 mL, 328 µmol, 4.88 equiv). The reaction was allowed to rise to room temperature and stirred for overnight. At this time, analytical RP-HPLC showed that a vancomycin peak still existed. Further addition of HBTU (10 mg, 26 µmol, 0.39 equiv) and DIEA (0.024 mL, 164 µmol, 2.44 equiv) was made. After another 24 h, the reaction was monitored with HPLC again and almost all vancomycin was found to have been consumed. To quench the reaction, the reaction mixture was added dropwise into 15 mL of acetone by using syringe. A white solid was precipitated out and filtered, and 5 mL of acetone was used to wash the solid once. The white solid was purified by reversedphase HPLC (RP-HPLC). The percentage yield is 52%. 1 , and VAZO (265 mg, 1.09 mmol, 0.2 equiv) in CCl4 (100 mL) was refluxed under nitrogen for 1 h, and the precipitated succinimide was removed immediately from the hot mixture by filtration. The precipitate was washed with CCl 4, and the combined CCl4 phases were evaporated. The remaining solid was dissolved in CH2Cl2 (100 mL) and extracted with 1 M Na2S2O3 solution (2 × 150 mL). The combined Na2S2O3 fractions were extracted with CH2Cl2 (50 mL), and the combined CH2Cl2 layers were dried by Na2SO4. The crude product was purified by flash column chromatography (silica gel, EtOAc/hexane, 1:4) and yielded 412 mg (22%) to give white solid. 1 5,5′-Bis(azidomethyl)-2,2′-bipyridine (7b). NaN3 (42 mg, 0.64 mmol, 2.2 equiv) was added to a solution of 5,5′-bis-(bromomethyl)-2,2′-bipyridine (100 mg, 0.29 mmol, 1 equiv) in dry DMF (3 mL). The solution was heated for 17 h at 90°C and then concentrated under vacuum to yield a mixture, which was treated with CH2Cl2. The solid (NaBr) was filtered off, and the extract was concentrated in a vacuum to yield the product (white solid), which was purified by flash column chromatography (silica gel, EtOAc/hexane, 40/60) and yielded 69 mg (90%) of pure white solid. 1 5,5′-Bis(aminomethyl)-2,2′-bipyridine (7c). 10% Pd on activated carbon (15 mg) was dissolved in 1 mL of dry CH2Cl2 in a closed round-bottom flask with vigorous stirring. 6 M HCl was added to another round-bottom flask that contained zinc powder in order to generate hydrogen gas. These two roundbottom flasks were connected by a rubber pipe. Make sure that there is no leakage. An outlet was introduced in the roundbottom flask containing 10% Pd on activated carbon. 5,5′-bis-(azidomethyl)-2,2′-bipyridine (60 mg, 0.23 mmol, 1 equiv) in 2 mL of dry CH2Cl2 was added to the round-bottom flask contained 10% Pd on activated carbon 3 min after the outlet was introduced. The reaction was completed within 4 h. 10% Pd on activated carbon was filtered by Celite and CH 2Cl2 was dried to obtain 39 mg of white solid (yield, 80%). 1 B. In Vitro Study. Minimum concentrations of the Van, [Pt(en)(H2O)2](NO3)2+Van, and dimers of Van required to inhibit the growth of bacterial cells were measured using cation-adjusted Muller-Hinton broth as the growth media. One vancomycin-susceptible strain, one strain exhibiting low-level resistance to vancomycin, five strains exhibiting midlevel resistance to vancomycin, and four strains exhibiting highlevel resistance to vancomycin were used to determine the MIC values. The average MIC values for the last two cases were shown in Table 1 . The genotype of the strains was confirmed by PCR.
